COMBINED VACCINATION AGAINST YELLOW-FEVER AND TYPHOID-FEVER - A COMPARATIVE TRIAL

被引:27
作者
AMBROSCH, F [1 ]
FRITZELL, B [1 ]
GREGOR, J [1 ]
JONAS, S [1 ]
KOLLARITSCH, H [1 ]
TEULIERES, L [1 ]
WIEDERMANN, G [1 ]
机构
[1] PASTEUR MERIEUX SERUMS & VACCINES,MARNES COQUETTE,FRANCE
关键词
YELLOW FEVER; TYPHOID FEVER; COMBINED VACCINATION; TOLERABILITY; IMMUNOGENICITY;
D O I
10.1016/0264-410X(94)90267-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In order to evaluate a combination of yellow fever and typhoid fever vaccine, we conducted a controlled trial comparing reactogenicity and immunogenicity of Vi polysaccharide (ViPS) vaccine and yellow fever 17D (YF) vaccine after single, simultaneous and combined administration. The combined YF/ViPS vaccine was prepared by using the liquid ViPS vaccine as a diluent for the YF vaccine. The stability of such a reconstitution had been assessed in vitro. Safety was evaluated using a self-surveillance form and by repeated clinical visits. Immunogenicity was evaluated by a plaque reduction test for YF and by radioimmunoassay for ViPS. Tolerability was satisfactory in all groups. There was no increase in local or general reactions in groups receiving both vaccines, whether given simultaneously or combined. The serological response to ViPS was similar after single and simultaneous or combined administration. Interestingly, the immune response to YF was significantly enhanced in groups receiving the vaccines simultaneously or combined, suggesting a potential adjuvant effect of ViPS.
引用
收藏
页码:625 / 628
页数:4
相关论文
共 10 条
  • [1] PREVENTION OF TYPHOID-FEVER IN NEPAL WITH THE VI CAPSULAR POLYSACCHARIDE OF SALMONELLA-TYPHI - A PRELIMINARY-REPORT
    ACHARYA, IL
    LOWE, CU
    THAPA, R
    GURUBACHARYA, VL
    SHRESTHA, MB
    CADOZ, M
    SCHULZ, D
    ARMAND, J
    BRYLA, DA
    TROLLFORS, B
    CRAMTON, T
    SCHNEERSON, R
    ROBBINS, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (18) : 1101 - 1104
  • [2] AMBROSCH F, 1991, TRAVEL MED, V2, P144
  • [3] Ashcroft M T, 1967, Lancet, V2, P1056
  • [4] MODULATION OF LIPOPOLYSACCHARIDE-INDUCED PRODUCTION OF TUMOR-NECROSIS-FACTOR, INTERLEUKIN-1, AND INTERLEUKIN-6 BY SYNTHETIC PRECURSOR-IA OF LIPID-A
    FEIST, W
    ULMER, AJ
    WANG, MH
    MUSEHOLD, J
    SCHLUTER, C
    GERDES, J
    HERZBECK, H
    BRADE, H
    KUSUMOTO, S
    DIAMANTSTEIN, T
    RIETSCHEL, ET
    FLAD, HD
    [J]. FEMS MICROBIOLOGY IMMUNOLOGY, 1992, 89 (02): : 73 - 89
  • [5] FLAD HD, 1991, BEHRING I MITT, V88, P112
  • [6] THERMOSTABILITY AND EFFICACY IN THE FIELD OF A NEW, STABILIZED YELLOW-FEVER VIRUS-VACCINE
    GEORGES, AJ
    TIBLE, F
    MEUNIER, DMY
    GONZALEZ, JP
    BERAUD, AM
    SISSOKODYBDAHL, NR
    ABDULWAHID, S
    FRITZELL, B
    GIRARD, M
    GEORGESCOURBOT, MC
    [J]. VACCINE, 1985, 3 (03) : 313 - 315
  • [7] KLUGMAN KP, 1987, LANCET, V2, P1165
  • [8] ROBBINS JD, 1984, J INFECT DIS, V150, P22
  • [9] COMPARATIVE CLINICAL-STUDY OF A NEW 17D THERMOSTABLE YELLOW-FEVER VACCINE
    ROCHE, JC
    JOUAN, A
    BRISOU, B
    RODHAIN, R
    FRITZELL, B
    HANNOUN, C
    [J]. VACCINE, 1986, 4 (03) : 163 - 165
  • [10] SAFETY AND IMMUNOGENICITY OF 2 SALMONELLA-TYPHI VI-CAPSULAR POLYSACCHARIDE VACCINES
    TACKET, CO
    FERRECCIO, C
    ROBBINS, JB
    TSAI, CM
    SCHULZ, D
    CADOZ, M
    GOUDEAU, A
    LEVINE, MM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1986, 154 (02) : 342 - 345